Adult Bipolar Mania

An International, Multicenter, Double-blind, Randomized, Placebo-controlled, Phase IV Study of the Safety and Efficacy of Lithium Versus Placebo as an Add on to SEROQUEL XR (Quetiapine Fumarate) in Adult Patients With Acute Mania

The purpose of this study is to determine if lithium 600-1800 mg/day is effective when added to quetiapine fumarate extended release (quetiapine XR or SEROQUEL® XR) 400-800 mg/day in treating acute mania and if so, how it compares with placebo (a non-active capsule, like a sugar pill, that looks like lithium).

Study Overview

• Status: Completed
• Conditions: Acute Mania
• Intervention / Treatment: Drug: Quetiapine fumarate XR; Drug: Lithium; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 356
• Phase: Phase 4

Contacts and Locations

Study Locations

• Belgium
  • Cedex, Belgium
    • Research Site
  • Dendermonde, Belgium
    • Research Site
  • Montignies-sur-sambre, Belgium
    • Research Site
  • Overpelt, Belgium
    • Research Site
  • Tournai, Belgium
    • Research Site
• Bulgaria
  • Burgas, Bulgaria
    • Research Site
  • Cedex, Bulgaria
    • Research Site
  • Kazanlak, Bulgaria
    • Research Site
  • Pazardjik, Bulgaria
    • Research Site
  • Plovdiv, Bulgaria
    • Research Site
  • Radnevo, Bulgaria
    • Research Site
  • Sofia, Bulgaria
    • Research Site
• Germany
  • Berlin, Germany
    • Research Site
  • Cedex, Germany
    • Research Site
  • Mannheim, Germany
    • Research Site
  • Munchen, Germany
    • Research Site
  • Nurnberg, Germany
    • Research Site
  • BE
    • Berlin, BE, Germany
      • Research Site
  • NW
    • Koln, NW, Germany
      • Research Site
• India
  • Cedex, India
    • Research Site
  • Andh Prad
    • Visakhapatnam, Andh Prad, India
      • Research Site
  • Gujarat
    • Ahmedabad, Gujarat, India
      • Research Site
  • Karna
    • Bangalore, Karna, India
      • Research Site
    • Mangalore, Karna, India
      • Research Site
    • Manipal, Karna, India
      • Research Site
  • Mahara
    • Nashik, Mahara, India
      • Research Site
  • Rajasthan
    • Jaipur, Rajasthan, India
      • Research Site
  • Uttar Prad
    • Kanpur, Uttar Prad, India
      • Research Site
• Israel
  • Bat Yam, Israel
    • Research Site
  • Beer Ya'acov, Israel
    • Research Site
  • Cedex, Israel
    • Research Site
  • Haifa, Israel
    • Research Site
  • Petach-tikva, Israel
    • Research Site
  • Tel-hashomer, Israel
    • Research Site
• Poland
  • Bydgoszcz, Poland
    • Research Site
  • Cedex, Poland
    • Research Site
  • Choroszcz, Poland
    • Research Site
  • Gorlice, Poland
    • Research Site
  • Katowice, Poland
    • Research Site
  • Krakow, Poland
    • Research Site
  • Lublin, Poland
    • Research Site
  • Poznan, Poland
    • Research Site
• Russian Federation
  • Arkhangelsk, Russian Federation
    • Research Site
  • Cedex, Russian Federation
    • Research Site
  • Chita, Russian Federation
    • Research Site
  • Kazan, Russian Federation
    • Research Site
  • Moscow, Russian Federation
    • Research Site
  • Saratov, Russian Federation
    • Research Site
  • St Petersburg, Russian Federation
    • Research Site
  • St. Petersburg, Russian Federation
    • Research Site
  • Voronezh, Russian Federation
    • Research Site
• South Africa
  • Cape Town, South Africa
    • Research Site
  • Cedex, South Africa
    • Research Site
  • Johannesburg, South Africa
    • Research Site
  • Port Elizabeth, South Africa
    • Research Site
  • Free State
    • Bloemfontein, Free State, South Africa
      • Research Site
    • Vereeniging, Free State, South Africa
      • Research Site
  • W Cape
    • Worcester, W Cape, South Africa
      • Research Site
• Ukraine
  • Cedex, Ukraine
    • Research Site
  • Dnipropetrovsk, Ukraine
    • Research Site
  • Donetsk, Ukraine
    • Research Site
  • Kharkov, Ukraine
    • Research Site
  • Kiev, Ukraine
    • Research Site
  • Odessa, Ukraine
    • Research Site
  • Vinnitsia, Ukraine
    • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Provision of informed consent before any study procedures are performed.
• The patient must have a documented clinical diagnosis for bipolar I disorder, including recent episode manic or mixed, and being male of females age 18-65 years, inclusive.
• Patients may be outpatients or inpatients at enrollment visit, but all patients must be inpatients when randomized and remain inpatients until discharged at the discretion of the investigator.

Exclusion Criteria:

• The patient can not have had up to 8 mood episodes during the past 12 months and not been continuously hospitalized for acute bipolar for up to 3 weeks immediately before participating in the study.
• The patient can not have a past diagnosis of stroke or medically documented transient ischemic attacks (TIA) or a history of seizure disorder, except for febrile convulsions.
• The patient must not have received electroconvulsive treatment (ECT) within 90 days before participating in the study and in the doctors judgement pose a current suicidal or homicidal risk.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: 1; Seroquel XR and Lithium	Drug: Quetiapine fumarate XR; Oral treatment, once daily, Day 1 = 300 mg, Day 2 and thereafter 600 mg. Dose might be adjusted as from Day 3 by the discretion of the investigator.; Other Names: Seroquel XR; Drug: Lithium; Oral treatment, twice daily, Days 1 and 2 = 600 mg/day, Days 3-8 = 900 mg/day. Dose adjustment from day 9 to end of study will be at the discretion of the investigator.
Placebo Comparator: 2; Seroquel XR and placebo	Drug: Quetiapine fumarate XR; Oral treatment, once daily, Day 1 = 300 mg, Day 2 and thereafter 600 mg. Dose might be adjusted as from Day 3 by the discretion of the investigator.; Other Names: Seroquel XR; Drug: Placebo; Oral treatment twice daily.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to Final Assessment (Day 43)	The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in manic symptoms. Total score ≤12 indicates remission (13-19=minimal symptoms; 20-25=mild mania, 26-37=moderate mania, 38-60=severe mania).	Change in YMRS total score from baseline to Day 43.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The Number of Patients With Clinically Significant Response.	The number of patients with clinically significant response (defined as ≥50% reduction from baseline to Day 43 in the YMRS total score) was calculated. The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or 50% reduction) from baseline indicates a reduction (or improvement) in manic symptoms.	43 days (from baseline to Day 43)
Remission	The number of patients with clinically significant remission (defined as YMRS total score ≤12) from Days 8 to 43) was calculated. The Young Mania Rating Scale total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or 50% reduction) from baseline indicates a reduction (or improvement) in manic symptoms. Total score ≤12 indicates remission (13-19=minimal symptoms; 20-25=mild mania, 26-37=moderate mania, 38-60=severe mania).	Days 8 to 43
Change From Baseline to Day 43 in CGI-BP-S (Clinical Global Impressions for Bipolar Disorder-Severity of Illness)	The CGI-BP-S scale rates the severity of the patient's illness at the time of assessment and is scored from 1 to 7 (1=normal, not ill to 7=very severely ill). Higher CGI-BP-S scores indicate greater illness severity.	Change from baseline to Day 43.
Change From Baseline to Day 43 in CGI-BP-C (Clinical Global Impressions for Bipolar Disorder-Change From Preceding Phase)	The CGI-BP-C scale rates how much the patient's illness has improved or worsened compared to the phase immediately preceding treatment and is scored on a scale from 1 to 8 (1=very much improved to 7=very much worse; 8=not applicable). A missing score will be used when a scale scored as 8 (not applicable). CGI-BP-C scores >4 indicate worsening, while scores <4 indicate improvement.	Change from baseline to Day 43
Improvement of Overall Bipolar Illness	The number of patients with a CGI-BP-C of "Much" or "Very much" improved in overall bipolar illness assessment at Day 43 was calculated. The CGI-BP-C scale rates how much the patient's illness has improved or worsened compared to the phase immediately preceding treatment and is scored on a scale from 1 to 8 (1=very much improved to 7=very much worse; 8=not applicable). A missing score will be used when a scale scored as 8 (not applicable). CGI-BP-C scores >4 indicate worsening, while scores <4 indicate improvement.	Day 43.
Change From Baseline to Day 43 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score	The MADRS is a 10-item scale that evaluates depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. Higher MADRS scores indicate higher levels of depressive symptoms.	Change from baseline to Day 43.
Change From Baseline to Day 43 in Positive and Negative Syndrome Scale (PANSS) Total Score	The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score is the sum of all 30 individual-item scores and ranges from 30 to 210.A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.	Change from baseline to Day 43
Change From Baseline to Day 43 in PANSS Activation Subscale Score	The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS activation subscale score for effect on agitation and aggression is the sum of 6 PANSS individual items (ie, hostility, poor impulse control, excitement, uncooperativeness, poor rapport and tension) and ranges from 6 to 42. A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.	Change from baseline to Day 43
Change From Baseline to Day 43 in PANSS Positive Subscale Score	The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS positive subscale score is the sum of the 7 positive item scores (ie, delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution and hostility) and ranges from 7 to 49. A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.	Change from baseline to Day 43
Change From Baseline to Day 43 in Each YMRS Item Score No. 1	The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 1 (Elevated mood) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.	Change from baseline to Day 43
Change From Baseline to Day 43 in Each YMRS Item Score No. 2	The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 2 (increased motor activity-energy) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.	Change from baseline to Day 43
Change From Baseline to Day 43 in Each YMRS Item Score No. 3	The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 3 (sexual interest) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.	Change from baseline to Day 43
Change From Baseline to Day 43 in Each YMRS Item Score No. 4	The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 4 (sleep) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.	Change from baseline to Day 43
Change From Baseline to Day 43 in Each YMRS Item Score No. 5	The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 5 (Irritability) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.	Change from baseline to Day 43
Change From Baseline to Day 43 in Each YMRS Item Score No. 6	The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 6 (speech-rate and amount) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.	Change from baseline to Day 43
Change From Baseline to Day 43 in Each YMRS Item Score No. 7	The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 7 (language-thought disorder) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.	Change from baseline to Day 43
Change From Baseline to Day 43 in Each YMRS Item Score No. 8	The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 8 (content) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.	Change from baseline to Day 43
Change From Baseline to Day 43 in Each YMRS Item Score No. 9	The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. . This analysis is for Item 9 (disruptive-aggressive behavior) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.	Change from baseline to Day 43
Change From Baseline to Day 43 in Each YMRS Item Score No. 10	The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 10 (appearance) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.	Change from baseline to Day 43
Change From Baseline to Day 43 in Each YMRS Item Score No. 11	The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 11 (insight) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.	Change from baseline to Day 43

Collaborators and Investigators

• Sponsor: AstraZeneca
• Collaborators: Quintiles, Inc.
• Investigators: Study Director: Michael Castiglione, AstraZeneca; Principal Investigator: Michel Bourin, Professeur, Neurobiologie de l'anxiété et de la dépression Faculté de Médecine

Publications and helpful links

General Publications

• Bourin MS, Severus E, Schronen JP, Gass P, Szamosi J, Eriksson H, Chandrashekar H. Lithium as add-on to quetiapine XR in adult patients with acute mania: a 6-week, multicenter, double-blind, randomized, placebo-controlled study. Int J Bipolar Disord. 2014 Nov 8;2:14. doi: 10.1186/s40345-014-0014-9. eCollection 2014.

Study record dates

Study Major Dates

• Study Start: June 1, 2009
• Primary Completion (Actual): November 1, 2010
• Study Completion (Actual): November 1, 2010

Study Registration Dates

• First Submitted: June 29, 2009
• First Submitted That Met QC Criteria: July 1, 2009
• First Posted (Estimate): July 2, 2009

Study Record Updates

• Last Update Posted (Estimate): April 19, 2012
• Last Update Submitted That Met QC Criteria: March 27, 2012
• Last Verified: March 1, 2012

More Information

Terms related to this study

• Keywords: Seroquel; Acute Mania; Mania, Adults; Acute Mania in Adult Patients
• Additional Relevant MeSH Terms: Mental Disorders; Nervous System Diseases; Neurologic Manifestations; Neurobehavioral Manifestations; Bipolar and Related Disorders; Bipolar Disorder; Mania; Physiological Effects of Drugs; Central Nervous System Depressants; Antipsychotic Agents; Tranquilizing Agents; Psychotropic Drugs; Antidepressive Agents; Quetiapine Fumarate
• Other Study ID Numbers: D144AC00003